HSA
CCCC icon

Hussman Strategic Advisors’s C4 Therapeutics CCCC Stock Holding History

Hussman Strategic Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-42,000
Closed -$239K – 248
2024
Q3 		$239K Hold
42,000
– – 0.06% 183
2024
Q2 		$194K Buy
+42,000
New +$250K 0.05% 203

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hussman Strategic Advisors's CCCC Position: Q4 2024 in Review

Hussman Strategic Advisors sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 42,000 shares — an estimated $239K sold.

Hussman Strategic Advisors first reported a position in CCCC in Q2 2024 and held it in 2 quarters. The position peaked at $239K in Q3 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Hussman Strategic Advisors reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Hussman Strategic Advisors sold 42,000 C4 Therapeutics shares in Q4 2024, an estimated $239K.
  • Hussman Strategic Advisors first reported a position in C4 Therapeutics in Q2 2024 and held it in 2 quarters.
  • Hussman Strategic Advisors's C4 Therapeutics position peaked at $239K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Hussman Strategic Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.